70%
of agricultural biologicals fail to deliver claimed field performance
$44B
global market with no scientific validation standard
17+
years of primary field research across South American soil systems
How QBA Helps
The Problem We Solve
Founders are more sophisticated than ever. AI has made pitch decks more polished and data-rich. But lab science is not commercial agriculture — and the gap between a promising bacterial strain and a product that actually works in farmers’ fields is where most biologicals investments lose value.
01
Pre-Investment
Technical Validation
QBIView™ Technology Assessment
Most biological claims don’t survive close scrutiny. QBIView™ is QBA’s proprietary due diligence framework — a structured, evidence-based assessment that tells you what the pitch deck doesn’t.
Every assessment applies our 7 Readiness Layers framework: Science Foundation, Biological Product Integrity, Regulatory Readiness, Commercial Viability, Organizational & IP Strength, R&D Culture, and Capital & Governance Integrity. Each layer is scored independently. Weaknesses don’t hide behind strengths.
Deliverables include a structured technical interview, independent patent landscape search across CIPO, USPTO, EPO, INPI, and WIPO, regulatory pathway assessment with realistic timelines, competitive benchmarking, and probability scenarios for the three most likely commercial outcomes.
The report closes with a QBA Verdict (Go / Conditional / No-Go) and specific deal term restructuring recommendations. You don’t just learn what the risks are — you learn how to structure around them.
02
Ongoing Portfolio
Inteligência
QBA Partnership Retainer
Biological markets move faster than most investors track. Regulatory decisions, emerging strain data, competitive approvals, and field trial failures reshape the landscape continuously — and most of it never surfaces in pitch decks or press releases.
The QBA Partnership retainer keeps you informed on the science that affects what you already own. We monitor regulatory developments at PMRA, CFIA, and EPA; track competitive product approvals and IP filings; apply machine learning tools to pattern-match emerging biological technologies against historical commercialization data; and flag early signals of portfolio company risk before they become board-level problems.
For funds with multiple biologicals positions, this is the layer of scientific judgment that turns reactive portfolio management into proactive risk intelligence.
03
Brazilian Research
Network
Deal Origination
Brazil is the world’s most advanced commercial market for agricultural biologicals. The country’s regulatory framework, field trial infrastructure, and research output — anchored by Embrapa and leading federal universities — is producing innovations that most North American investors encounter only after valuations have already climbed.
QBA holds direct research relationships with the Embrapa network and Brazilian academic institutions built over 17+ years of primary field research across South American soil systems. We surface technologies at the stage where scientific validation is possible and deal terms are still favorable — and we assess them using the same QBIView™ framework before you take a meeting.
If you’re building a biologicals portfolio and not watching Brazil, you’re watching the wrong market.
Ready to de-risk your next investment?
Let’s talk about your next
biologicals decision.
Schedule a 20-minute consultation to discuss how Quadros Bio Advisory can help you separate credible biology from compelling pitch decks.
Agendar uma ligação